Neuralstem to Collaborate with University of Michigan ALS Clinic

ROCKVILLE, Maryland, August 30 /PRNewswire/ --

- to Explore Neuralstem Cells' Potential in Lou Gehrig's Disease
Treatment

Stem cell company, Neuralstem, Inc. (Amex: CUR), today announced it has
entered into a collaborative agreement with the ALS Clinic at University of
Michigan Health System, directed by Dr. Eva Feldman, M.D., Ph.D., the De Jong
Professor of Neurology at the U-M Medical School. The goal of the
collaboration is to provide further proof-of-principle data to move
Neuralstem's spinal cord stem cells into patients with Amyotrophic Lateral
Sclerosis (ALS), or Lou Gehrig's disease. ALS is a motor neuron disease,
which strikes people between the ages of 40 and 70. As many as 30,000
Americans have the disease at any given time.

"We are honored and excited to be working with Dr. Feldman and the
University of Michigan ALS Clinic," said Neuralstem CEO, Richard Garr. "It is
not only a world class research organization, but also clearly dedicated to,
and deeply involved in, the care and treatment of the ALS patients
themselves. Dr. Feldman and her team will be a tremendous partner in helping
us to achieve our goal, which is to be able to treat ALS patients with our
Neuralstem cells."

"We are excited about working with Neuralstem's technology and exploring
the ways in which it might lead to treatment for ALS patients," said Dr.
Feldman, who is also the Director at the U-M Program for Neurology Research
and Discovery, "At the Michigan ALS clinic, we are working as hard and as
fast as we can to try to find treatments for this terrible disease."

About Neuralstem

Neuralstem's patent-protected technology enables, for the first time, the
ability to produce neural stem cells of the human brain and spinal cord in
commercial quantities, and the ability to control the differentiation of
these cells into mature, physiologically relevant human neurons and glia. The
Company expects that its first Investigational New Drug (IND) application
will be for the treatment of Ischemic Paraplegia, a form of paraplegia that
sometimes results from the surgery to repair aortic aneurysms and for which
there is no effective treatment. The Company hopes to submit its initial IND
application to the FDA and begin its first human trial during calendar year
2007.

Major Central Nervous System diseases targeted by the Company with
research programs currently underway include: Ischemic Paraplegia, Traumatic
Spinal Cord Injury, ALS, and Parkinson's disease. The company's cells
recently extended the life of rats with ALS (Lou Gehrig's disease) in a paper
published in the journal TRANSPLANTATION, and were deemed viable for
continued work in neurodegenerative spinal conditions. Neuralstem cells also
recently reversed paralysis in rats with Ischemic Spastic Paraplegia, a form
of paralysis that can result from the surgery to repair aortic aneurysms, as
reported in NEUROSCIENCE (http://www.neuroscience-ibro.com/ ). The company
has also developed immortalized human neural stem cells for in-vitro use in
drug development for the academic and pharmaceutical markets. For further
information, please visit http://www.neuralstem.com .

Cautionary Statement Regarding Forward Looking Information

This presentation may contain forward-looking information about
Neuralstem, Inc. which are intended to be covered by the safe harbor for
forward-looking statements provided by the Private Securities Litigation
Reform Act of 1995. Forward- looking statements are statements that are not
historical facts. These statements can be identified by the use of
forward-looking terminology such as "believe," "expect," "may," "will,"
"should," "project," "plan," "seek," "intend," or "anticipate" or the
negative thereof or comparable terminology, and include discussions of
strategy, and statements about industry trends and Neuralstem's future
performance, operations and products. This and other "Risk Factors" contained
in Neuralstem's public filings with the SEC should be read in connection with
this release. For further information on Neuralstem, please review the
company's filings with the SEC including its Annual Report filed on Form
10-KSB for the period ended December 31, 2006, as well as the company's
subsequent filings.

Web site: http://www.neuralstem.com
              http://www.neuroscience-ibro.com